MARKET OVERVIEW:
The global macular degeneration treatment market was valued at USD 9.9 billion in 2024 and is projected to reach USD 15.8 billion by 2033, growing at a CAGR of 5.28% during the forecast period. This growth is primarily driven by the increasing prevalence of age-related macular degeneration (AMD) and obesity, coupled with the rising adoption of treatments aimed at enhancing vision and reducing the risk of blindness.
STUDY ASSUMPTION YEARS:
- Base Year: 2024
- Historical Years: 2019-2024
- Forecast Years: 2025-2033
MACULAR DEGENERATION TREATMENT MARKET KEY TAKEAWAYS:
- Market Size and Growth: The market was valued at USD 9.9 billion in 2024 and is expected to reach USD 15.8 billion by 2033, reflecting a CAGR of 5.28%.
- Dominant Region: North America leads the market, attributed to advanced healthcare infrastructure and high adoption rates of treatment options.
- Prevalent Type: Wet age-related macular degeneration currently holds the majority of the market share.
- Late-Stage Cases: Late-stage AMD cases dominate the market, emphasizing the need for advanced treatment options.
- Treatment Route Preference: The intravitreal route of administration is preferred, offering targeted delivery of therapeutic agents.
- Hospital-Centric Care: Hospitals are the primary end-users of macular degeneration treatments, providing specialized care for patients.
- Technological Advancements: Ongoing research and development are leading to innovative treatments, enhancing patient outcomes and driving market growth.
MARKET GROWTH FACTORS:
Continuous Technological Progress: Among the routinely upgrading macular degeneration treatments-techniques, they include the innovations made in diagnostics, and therapeutic technologies. The recent advancements, for instance, retinal gene therapies, and less invasive techniques, enhance patient prognosis. Meanwhile, they lower treatment-associated risks, upsurge investment levels from pharmaceutical companies, and power the continued rises in market growth.
Regulatory Impact: This is a booster in regulatory frameworks that indirectly promote government support and incorporate approvals for new treatments into the market, thereby benefitting the patients in outpatient costs. Drug and therapy innovations facilitate expedited drug approval, thus affording patients access to timely and effective treatment. Hence, reimbursement policies and health funding complement market growth regarding the affordability and accessibility of treatments for macular degeneration.
Market Time Trend: More specifically, the elderly now have awareness of treatment options, increasing demand for macular degeneration treatments. There will now be awareness campaigns and improved patient awareness for earlier diagnosis and treatment of cases, which could prevent much more serious vision loss. Such an increase creates opportunities to the practitioners for providing the latest services applying the advanced treatment modalities to maintain the growth of the market.
Request Sample For PDF Report: https://www.imarcgroup.com/macular-degeneration-treatment-market/requestsample
Market Segmentation:
Breakup by Type:
- Dry Age-related Macular Degeneration
- Wet Age-related Macular Degeneration
Breakup by Stage of Disease:
- Early Stage
- Intermediate Stage
- Late Stage
Breakup by Route of Administration:
- Intravenous Route
- Intravitreal Route
Breakup by End User:
- Hospitals
- Ambulatory Surgical Center
- Others
Market Breakup by Region:
- North America (United States, Canada)
- Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, Others)
- Europe (Germany, France, United Kingdom, Italy, Spain, Russia, Others)
- Latin America (Brazil, Mexico, Others)
- Middle East and Africa
Key Players:
- Aerie Pharmaceuticals Inc.
- Bausch Health Companies Inc.
- Bayer AG
- F. Hoffmann-La Roche Ltd
- Iveric Bio Inc.
- Novartis AG
- Panoptica
- Pfizer Inc.
- Phio Pharmaceuticals
- Regeneron Pharmaceuticals Inc.
- Regenxbio Inc.
- Santen Pharmaceutical Co. Ltd.
Note: If you need specific information that is not currently within the scope of the report, we will provide it to you as a part of the customization.
About Us:
IMARC Group is a global management consulting firm that helps the world’s most ambitious changemakers to create a lasting impact. The company provide a comprehensive suite of market entry and expansion services. IMARC offerings include thorough market assessment, feasibility studies, company incorporation assistance, factory setup support, regulatory approvals and licensing navigation, branding, marketing and sales strategies, competitive landscape and benchmarking analyses, pricing and cost research, and procurement research.
